Qiming Venture Partners
VC Fund
Shanghai, China
Qiming Venture Partners is a VC fund in Shanghai focused on Health Care and Biotechnology. Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages. Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
- Total investments:
- 1200
- Last investment:
- Lead investor:
- 51%
- Fund size:
- $8M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Qiming Venture Partners invests in
Stages Qiming Venture Partners invests in
Countries Qiming Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 17 contacts → | |||
Round size
- Series A
- $4.3M–$48M
- Series B
- $8M–$90M
- Series C
- $12M–$120M
Investment Focus
Industry
- Health Care 149 (12%)
- Biotechnology 122 (10%)
- Medical 118 (10%)
- Pharmaceutical 58 (5%)
- Manufacturing 57 (5%)
Stage
- Series B 253 (21%)
- Series A 244 (20%)
- Series C 137 (11%)
- Seed 77 (6%)
- Series D 54 (5%)
Country
- China 452 (38%)
- United States 68 (6%)
- Hong Kong 12 (1%)
- Singapore 10 (1%)
- Taiwan 3 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Grace Lee
Partner & CFO
|
Partner & CFO | Total investments: 0 | Find email | |
Jinda Gao
Principal
|
Principal | Total investments: 11 | Find email | |
Oscar Zhang
Principal
|
Principal | Total investments: 27 | Find email | |
Shiyu Wang
Partner
|
Partner | Total investments: 13 | Find email | |
Alexander Sinclair-Wilson
Principal
|
Principal | Total investments: 4 | Find email | |
| See all 17 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Allygen Biologics
|
Allygen Biologics is a biotechnology company that provides research and development of targeted conjugate therapeutics. | $44.8M / Series A / Oct 13, 2026 | |
| Baiqu Bio is a high-tech enterprise specializing in the application, consulting and development of cutting-edge research technology in life sciences. It is also an early detection and analysis service organization for comprehensive solutions of metabolomics in China. The company's core team has extensive experience in the field of metabolomicsin scientific research services, health testing, and industrial testing. Baiqu Bio focuses on mass spectrometry and metabolic testing, and continues to develop and research on metabolomics product innovation and technology. At present, it has a number of metabolomics patents, masters the core technology in the field of metabolomics, and is proud of the domestic metabolomics detection and analysis field. Achievements. Since its inception, the company's performance has maintained a steady growth momentum for consecutive years and has achieved profitability for six consecutive years. | $14.9M / Series B / Oct 10, 2026 | ||
| Xuntu Technology is a leading data intelligence provider specializing in investment research and decision-making solutions. | $44.7M / Series B / Sep 10, 2026 | ||
| Sharpa is a robotics company that develops robots and core robotic components for real-world deployment of robotic applications. | $668.8M / Venture - Series Unknown / Aug 28, 2026 | ||
| AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $120M / Series C / Aug 27, 2026 | ||
|
Chiplight Technology
|
Chipligh Technology develops optical interconnect and silicon photonics solutions for AI computing clusters. | $14.9M / Seed / Aug 25, 2026 | |
Enginprime Medical
|
Enginprime Medical is an enterprise focusing on the research and development and transformation of innovative medical technologies in the cardiovascular field, with a focus on the percutaneous ventricular assist device (pVAD) track, and is committed to developing a new generation of small-size, high-flow ventricular assist systems. | $12M / Series A / Aug 17, 2026 | |
|
Blue Emergence
|
Blue Emergence is a marine technology consumer products company, | Angel / Jul 24, 2026 | |
Fibrox
|
Fibrox develops innovative cell therapies based on fibroblasts and clinical requirements for patients. | $3.7M / Series A / Jul 21, 2026 | |
| Mufan Power is a new energy high-tech enterprise in the field of turbomachinery. It is committed to the development of a new generation of zero-carbon hydrogen power generation technologies and products. Its main products are hydrogen gas turbines, which can be used in distributed energy and data centers. , rail transit, ship power, vehicle power,energy storage peak shaving and other carbon neutral scenarios. | Series C / Jul 13, 2026 | ||
| See all 1200 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Qiming Venture Partners invest in?
Qiming Venture Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 1,200 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Qiming Venture Partners invest in?
Qiming Venture Partners typically joins rounds of $4.3M–$48M at Series A, $8M–$90M at Series B and $12M–$120M at Series C. These are whole funding-round sizes, not Qiming Venture Partners's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Qiming Venture Partners took part in.
How do I contact Qiming Venture Partners?
Public channels for Qiming Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Qiming Venture Partners?
The team at Qiming Venture Partners includes Grace Lee (Partner & CFO), Jinda Gao (Principal) and Oscar Zhang (Principal), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
